Polycomb repressive complexes in hematological malignancies
Polycomb repressive complexes in hematological malignancies
复制标题
DOI：
10.1182/blood-2017-02-739490
复制
发表时间：
2017-07-06
期刊：
影响因子：
20.3
通讯作者：
Iwama, Atsushi
中科院分区：
文献类型：
--
作者：
Iwama, Atsushi
多梳抑制复合体(PRCs)的去调控在一些血液系统恶性肿瘤中已有报道。根据肿瘤类型的不同，这些复合体发挥致癌或抑瘤功能。这些发现彻底改变了我们对血液系统恶性肿瘤的病理生理学以及去调控的表观基因组在肿瘤发生和发展中的影响的理解。PRCs的靶向治疗目前正受到越来越多的关注，并在临床研究中得到了广泛的研究，导致了新的治疗策略，可能会改善血液系统恶性肿瘤患者的预后。
The deregulation of polycomb repressive complexes (PRCs) has been reported in a number of hematological malignancies. These complexes exert oncogenic or tumor-suppressive functions depending on tumor type. These findings have revolutionized our understanding of the pathophysiology of hematological malignancies and the impact of deregulated epigenomes in tumor development and progression. The therapeutic targeting of PRCs is currently attracting increasing attention and being extensively examined in clinical studies, leading to new therapeutic strategies that may improve the outcomes of patients with hematological malignancies.